879 Post-treatment neutrophil-to-lymphocyte ratio and gMDSCs as independent prognostic factors for treatment efficacy with monoclonal antibody NEO-201 and pembrolizumab
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797637833976971264 |
|---|---|
| author | Massimo Fantini Kwong Y Tsang Christina Annunziata Philip Arlen Anjum Zaki Sharon Mavroukakis Charalampos S Floudas Jamie Hur Azam Ghafoor Ann McCoy Erica Redmond Christine Feierabend |
| author_facet | Massimo Fantini Kwong Y Tsang Christina Annunziata Philip Arlen Anjum Zaki Sharon Mavroukakis Charalampos S Floudas Jamie Hur Azam Ghafoor Ann McCoy Erica Redmond Christine Feierabend |
| author_sort | Massimo Fantini |
| collection | DOAJ |
| first_indexed | 2024-03-11T12:54:57Z |
| format | Article |
| id | doaj.art-db95603f19224ab78a0c8f0e533912fb |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T12:54:57Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-db95603f19224ab78a0c8f0e533912fb2023-11-03T20:55:09ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0879879 Post-treatment neutrophil-to-lymphocyte ratio and gMDSCs as independent prognostic factors for treatment efficacy with monoclonal antibody NEO-201 and pembrolizumabMassimo Fantini0Kwong Y Tsang1Christina Annunziata2Philip Arlen3Anjum Zaki4Sharon Mavroukakis5Charalampos S Floudas6Jamie Hur7Azam Ghafoor8Ann McCoy9Erica Redmond10Christine Feierabend112Precision Biologics, Inc., Bethesda, MD, USA2Precision Biologics, Inc., Bethesda, MD, USA1National Institutes of Health (NIH), Bethesda, MD, USA2Precision Biologics, Inc., Bethesda, MD, USA2Precision Biologics, Inc., Bethesda, MD, USA2Precision Biologics, Inc., Bethesda, MD, USA3National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA1National Institutes of Health (NIH), Bethesda, MD, USA1National Institutes of Health (NIH), Bethesda, MD, USA1National Institutes of Health (NIH), Bethesda, MD, USA1National Institutes of Health (NIH), Bethesda, MD, USA1National Institutes of Health (NIH), Bethesda, MD, USA |
| spellingShingle | Massimo Fantini Kwong Y Tsang Christina Annunziata Philip Arlen Anjum Zaki Sharon Mavroukakis Charalampos S Floudas Jamie Hur Azam Ghafoor Ann McCoy Erica Redmond Christine Feierabend 879 Post-treatment neutrophil-to-lymphocyte ratio and gMDSCs as independent prognostic factors for treatment efficacy with monoclonal antibody NEO-201 and pembrolizumab Journal for ImmunoTherapy of Cancer |
| title | 879 Post-treatment neutrophil-to-lymphocyte ratio and gMDSCs as independent prognostic factors for treatment efficacy with monoclonal antibody NEO-201 and pembrolizumab |
| title_full | 879 Post-treatment neutrophil-to-lymphocyte ratio and gMDSCs as independent prognostic factors for treatment efficacy with monoclonal antibody NEO-201 and pembrolizumab |
| title_fullStr | 879 Post-treatment neutrophil-to-lymphocyte ratio and gMDSCs as independent prognostic factors for treatment efficacy with monoclonal antibody NEO-201 and pembrolizumab |
| title_full_unstemmed | 879 Post-treatment neutrophil-to-lymphocyte ratio and gMDSCs as independent prognostic factors for treatment efficacy with monoclonal antibody NEO-201 and pembrolizumab |
| title_short | 879 Post-treatment neutrophil-to-lymphocyte ratio and gMDSCs as independent prognostic factors for treatment efficacy with monoclonal antibody NEO-201 and pembrolizumab |
| title_sort | 879 post treatment neutrophil to lymphocyte ratio and gmdscs as independent prognostic factors for treatment efficacy with monoclonal antibody neo 201 and pembrolizumab |
| work_keys_str_mv | AT massimofantini 879posttreatmentneutrophiltolymphocyteratioandgmdscsasindependentprognosticfactorsfortreatmentefficacywithmonoclonalantibodyneo201andpembrolizumab AT kwongytsang 879posttreatmentneutrophiltolymphocyteratioandgmdscsasindependentprognosticfactorsfortreatmentefficacywithmonoclonalantibodyneo201andpembrolizumab AT christinaannunziata 879posttreatmentneutrophiltolymphocyteratioandgmdscsasindependentprognosticfactorsfortreatmentefficacywithmonoclonalantibodyneo201andpembrolizumab AT philiparlen 879posttreatmentneutrophiltolymphocyteratioandgmdscsasindependentprognosticfactorsfortreatmentefficacywithmonoclonalantibodyneo201andpembrolizumab AT anjumzaki 879posttreatmentneutrophiltolymphocyteratioandgmdscsasindependentprognosticfactorsfortreatmentefficacywithmonoclonalantibodyneo201andpembrolizumab AT sharonmavroukakis 879posttreatmentneutrophiltolymphocyteratioandgmdscsasindependentprognosticfactorsfortreatmentefficacywithmonoclonalantibodyneo201andpembrolizumab AT charalampossfloudas 879posttreatmentneutrophiltolymphocyteratioandgmdscsasindependentprognosticfactorsfortreatmentefficacywithmonoclonalantibodyneo201andpembrolizumab AT jamiehur 879posttreatmentneutrophiltolymphocyteratioandgmdscsasindependentprognosticfactorsfortreatmentefficacywithmonoclonalantibodyneo201andpembrolizumab AT azamghafoor 879posttreatmentneutrophiltolymphocyteratioandgmdscsasindependentprognosticfactorsfortreatmentefficacywithmonoclonalantibodyneo201andpembrolizumab AT annmccoy 879posttreatmentneutrophiltolymphocyteratioandgmdscsasindependentprognosticfactorsfortreatmentefficacywithmonoclonalantibodyneo201andpembrolizumab AT ericaredmond 879posttreatmentneutrophiltolymphocyteratioandgmdscsasindependentprognosticfactorsfortreatmentefficacywithmonoclonalantibodyneo201andpembrolizumab AT christinefeierabend 879posttreatmentneutrophiltolymphocyteratioandgmdscsasindependentprognosticfactorsfortreatmentefficacywithmonoclonalantibodyneo201andpembrolizumab |